A 4-methyl-substituted meta-iodobenzylguanidine analogue with prolonged retention in human neuroblastoma cells

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 31, Issue 10, 2004, Pages 1362-1370

  Vaidyanathan, Ganesan ^a   Welsh, Philip C ^a   Vitorello, Katia C ^a   Snyder, Stacey ^a   Friedman, Henry S ^a   Zalutsky, Michael R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

3 Iodo 4 methyl benzylguanidine; IMR32 xenograft; MIBG; Neuroblastoma; SK N SH xenograft

Indexed keywords

(3 IODOBENZYL)GUANIDINE; (3 IODOBENZYL)GUANIDINE I 125; (3 IODOBENZYL)GUANIDINE I 131; 3 IODO 4 METHYL BENZYLGUANIDINE I 131; DESIPRAMINE; METHYL GROUP; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG LIVER LEVEL; DRUG STRUCTURE; DRUG TISSUE LEVEL; DRUG UPTAKE; HUMAN; HUMAN CELL; IN VITRO STUDY; ISOTOPE LABELING; MOUSE; NEUROBLASTOMA CELL; NEUROENDOCRINE TUMOR; NONHUMAN; NUDE MOUSE; RADIOISOTOPE THERAPY; TUMOR XENOGRAFT;

3-IODOBENZYLGUANIDINE; ANIMALS; CELL LINE, TUMOR; HUMANS; MALE; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEUROBLASTOMA; ORGAN SPECIFICITY; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION;

EID: 5444270462     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-004-1596-8     Document Type: Article

References (36)

1. Patel AD, Iskandrian AE. MIBG imaging. J Nucl Cardiol 2002;9:75-94
2. Hattori N, Schwaiger M. Metaiodobenzylguanidine scintigraphy of the heart: what have we learnt clinlcally? Eur J Nucl Med 2000;27:1-6
3. Sisson JC, Shulkin BL. Nuclear medicine imaging of pheochromocytoma and neuroblastoma. Q J Nucl Med 1999; 43:217-23
4. 131I-MIBG. J Nucl Med 2001;42:237-47
5. 131I MIBG therapy in neuroblastoma: mechanisms, rationale, and current status. Med Pediatr Oncol 1999;32:427-31
6. 131I-mIBG). Clin Endocrinol 2001;55:47-60
7. 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol 1998;16:229-36
8. Yanik GA, Levine JE, Matthay KK, Yanik GA, Levine JE, Matthay KK, Sisson JC, Shulkin BL, Shapiro B, Hubers D, Spalding S, Braun T, Ferrara JLM, Hutchinson RJ. Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma. J Clin Oncol 2002;20:2142-9
9. Vaidyanathan G, Shankar S, Affleck DJ, Welsh PC, Slade SK, Zalutsky MR. Biological evaluation of ring- and side-chain-substituted m-iodobenzylguanidine analogues. Bioconjug Chem 2001;12:798-806
10. Vaidyanathan G, Affleck DJ, Zalutsky MR Validation of 4-[fluorine-18]fluoro-3-iodobenzylguanidine as a positron-emitting analog of MIBG. J Nucl Med 1995;36:644-50
11. Wieland DM Radiopharmaceutical design: the adrenal medulla and its diseases. In: Fritzberg AR, ed. Radiopharmaceuticals: progress and clinical perspectives, vol 1. Boca Raton: CRC; 1986.117-53
12. Sircar I, Duell BL, Bobowski G, Bristol JA, Evans DB. Cardiotonic agents. 2. Synthesis and structure-activity relationships of 4,5-dihydro-6-[4-(1H- imidazol-1-yl)phenyl]-3(2H)-pyridazinones: a new class of positive inotropic agents. J Med Chem 1985;28:1405-13
13. Block MH, Boyer S, Brailsford W, Brittain DR, Carroll D, Chapman S, Clarke DS, Donald CS, Foote KM, Godfrey L, Ladner A, Marsham PR, Masters DJ, Mee CD, O'Donovan MR, Pease JE, Pickup AG, Rayner JW, Roberts A, Schofield P, Suleman A, Turnbull AV Discovery and optimization of a series of carbazole ureas as NPY5 antagonists for the treatment of obesity. J Med Chem 2002;45:3509-23
14. Vaidyanathan G, Shankar S, Affleck DJ, Alston K, Norman J, Welsh P, LeGrand H, Zalutsky MR. Meta-iodobenzylguanidine derivatives containing a second guanidine moiety. Bioorg Med Chem 2004;12:1649-56
15. Jaques S Jr, Tobes MC, Sisson JC, Baker JA, Wieland DM. Comparison of the sodium dependency of uptake of metaiodobenzylguanidine and norepinephrine into cultured bovine adrenomedullary cells. Mol Pharmacol 1984;26:539-46
16. Smets LA, Loesberg C, Janssen M, Metwally EA, Huiskamp R Active uptake and extravesicular storage of m-iodobenzylguanidine in human neuroblastoma SK-N-SH cells. Cancer Res 1989;49:2941-4
17. 131I]iodobenzylguanidine. J Nucl Med 1980;21:349-53
18. 131I]iodobenzylguanidine. Appl Radiat Isot 1993; 44:621-8
19. Biedler JN, Helson L, Spengler BA. Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture. Cancer Res 1973;33:2643-52
20. Kaltenbach JP, Kaltenbach MH, Lyons WB. Nigrosin as a dye for differentiating live and dead ascites cells Exp Cell Res 1958;15:112-7
21. Vaidyanathan G, Affleck DJ, Zalutsky MR. Validation of 4-[fluorine-18]fluoro-3-iodobenzylguanidine as a positron-emitting analog of MIBG J Nucl Med 1995;36:644-50
22. Lee H, Inbasekaran MN, Wieland DM, Sherman PS, Fisher SJ, Mangner TJ, Rogers WL, Clinthorne NH. Development of a kit-form analog of metaiodobenzylguanidine. J Nucl Med 1986;27:256-67
23. Mairs RJ, Gaze MN, Barrett A. The uptake and retention of metaiodobenzylguanidine by the neuroblastoma cell line NB1-G Br J Cancer 1991;64:293-5
24. Vaidyanathan G, Zhao X-G, Strickland DK, Zalutsky MR. No-camer-added iodine-131-FIBG, evaluation of an MIBG analog. J Nucl Med 1997;38:330-4
25. Kelley SP, Grota LJ, Felten SY, Madden KS, Felten DL Norepinephrine in mouse spleen shows minor strain differences and no diurnal variation. Pharmacol Biochem Behav 1996;53:141-6
26. Cano G, Sved AF, Rinaman L, Rabin BS, Card JP. Characterization of the central nervous system innervation of the rat spleen using viral transneuronal tracing. J Comp Neurol 2001;439:1-18
27. Rutgers M, Tytgat GAM, Verwijs-Janssen M, Buitenhusis C, Voute PA. Smets LA Uptake of the neuron-blocking agent meta-iodobenzylguanidine and serotonin by human platelets and neuro-adrenergic tumor cells. Int J Cancer 1993;54:290-5
28. Glowniak JV, Kilty JE, Amara SG, Hoffman BJ, Turner FE. Evaluation of metaiodobenzylguanidine uptake by the norepinephrine, dopamine and serotonin transporters. J Nucl Med 1993;34:1140-6
29. 131I-meta-iodobenzylguanidine. Metabolism 1984;33:397-9
30. 131I]-metaiodobenzylguanidine (MIBG) biodistribution and targeted radiotherapy. Prog Clin Biol Res 1991;366:471-8
31. Khanna C, Jaboin JJ, Drakos E, Tsokos M, Thiele CJ. Biologically relevant orthotopic neuroblastoma xenograft models: primary adrenal tumor growth and spontaneous distant metastasis. In Vivo 2002;16:77-86
32. 125I]iodobenzylguanidine in the human neuroblastoma cell line SK-N-SH. Cancer Res 1995;45:6366-70
33. Armour A, Mairs RJ, Gaze MN, Wheldon TE. Modification of meta-iodobenzylguanidine uptake in neuroblastoma cells by elevated temperature. Br J Cancer 1994;70:445-8
34. Montaldo PG, Raffaghello L, Guarnaccia F, Pistoia V, Garaventa A, Ponzoni M. Increase of metaiodobenzylguanidine uptake and intracellular half-life during differentiation of human neuroblastoma cells Int J Cancer 1996;67:95-100
35. Driscoll TA, Flowers JL, Colvin OM. Potentiation of camptothecin-based antineuroblastoma activity by selective tumor acidification [abstract]. Proc Am Assoc Cancer Res 2002, Abstract 2888
36. 131I]MIBG in nude mice bearing SK-N-SH human neuroblastoma xenografts: effects of specific activity. Br J Cancer 1996;73.1171-7